Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 6:8:9.
doi: 10.1186/s13045-014-0104-2.

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

Affiliations

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

Dat Nguyen et al. J Hematol Oncol. .

Abstract

Background: Notch1 transmembrane receptor is activated through ligand-binding- triggered proteolytic cleavages and, upon release, the intracellular domain (N1-ICD) translocates into the nucleus and modulates target gene transcriptions. Notch activation has been implicated in tumorigenesis in an increasing number of human malignancies including non-small cell lung cancer (NSCLC). However, Notch1 in distinct expression patterns and activation status with tumor progression remains to be defined in NSCLC.

Methods: Notch1 and activated Notch1, N1-ICD, were examined by immunohistochemistry in 58 cases of stage I to IV NSCLC tumors. Association between Notch1 or N1-ICD expression and clinicopathological factors was assessed via correlation coefficient r statistics. P-values are two-sided.

Results: Detectable tumor Notch1, predominantly localized to the membrane and cytoplasm, was observed in 29 cases (50%, 95% Blyth-Still-Casella confidence interval 37 - 63%). It was negatively associated with stage (r=- 0.43, P<0.001) and nodal status (r=- 0.33, P = 0.01), but not tumor size. In contrast, nuclear N1-ICD expression level was low and found in 12% of NSCLC patients, neither significantly associated with stage nor nodal status. Upon Notch1 activation in vitro, a mostly extra-nuclear staining was substantially turned into the nuclear signal in cancer cells.

Conclusions: Notch1 in the largely inactivated phenotype is inversely associated with clinical stage progression in NSCLC. Notch1, rather than activated N1-ICD, may be a context-dependent restrictive factor to nodal metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of Notch1, N1-ICD-V1754 and E-cadherin by Western blot and immunocytochemistry in cancer cells. Western blot analysis demonstrates specific bands of the respective proteins of Notch1, N1-ICD-V1754 and E-cadherin in MCF-7, NCI-H23 and NCI-H522 cells (A). Notch1 (a, c) and N1-ICD-V1754 (b, d) expression in formalin-fixed and paraffin-embedded NCI-H23 cells (B). Magnifications x600.
Figure 2
Figure 2
Confirmation of expression of Notch1, N1-ICD-V1754 and E-cadherin in additional NSCLC cells. Expression of Notch1, N1-ICD-V1754 and E-cadherin were analyzed using Western blot in NSCLC NCI-H358 and NCI-H322M cells (A). E-cadherin expression was examined by immunohistochemistry in NSCLC NCI-H358 and NCI H322M cell lines (B). Magnifications x600.
Figure 3
Figure 3
Representative staining patterns of Notch1, N1-ICD-V1754 and heterogeneous tumor cell proliferation (Ki67) in NSCLC tumor tissues. Notch1, N1-ICD-V1754 and Ki67 in a case of undifferentiated carcinoma of the lung, showing high level of membranous/cytoplasmic/nuclear Notch1 expression (A2), nuclear N1-ICD-V1754 (A3), and Ki67 labeling (A4). Notch1, N1-ICD-V1754 and Ki67 in a case of squamous cell carcinoma of the lung, displaying high level of cytoplasmic/membranous/nuclear Notch1staining (B2), heterogeneous N1-ICD-V1754 (B3), and Ki67 proliferation (B4). Notch1, N1-ICD-V1754 and Ki67 in a case of adenocarcinoma of the lung, exhibiting cytoplasmic/membranous Notch1 signal (C2) and some nuclear N1-ICD-V1754 staining on the right (C3), and Ki67 expression (C4). HE staining of undifferentiated carcinoma, squamous cell carcinoma and adenocarcinoma of the lung (A1, B1, and C1). Magnifications x200.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442(7104):823–6. doi: 10.1038/nature04940. - DOI - PubMed
    1. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–15. doi: 10.1186/bcr920. - DOI - PMC - PubMed
    1. Liu N, Zhang J, Ji C. The emerging roles of Notch signaling in leukemia and stem cells. Biomarker Res. 2013;1(1):23. doi: 10.1186/2050-7771-1-23. - DOI - PMC - PubMed
    1. Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3. doi: 10.1186/1756-8722-6-3. - DOI - PMC - PubMed